Unknown

Dataset Information

0

Survival following salvage therapy for primary refractory peripheral T-cell lymphomas (PTCL).


ABSTRACT: Optimal salvage therapy for primary refractory peripheral T-cell lymphomas (PTCL) and the role of hematopoietic stem cell transplant (SCT) remain poorly defined. We conducted a retrospective review of clinical outcomes and prognostic factors in a single-center cohort of 93 patients with primary refractory PTCL, defined as progression during first-line therapy or relapse within 6 months of its completion. Clinical outcomes were poor in this population, with median event-free survival (EFS) of 3.5 months, median overall survival (OS) of 9.1 months, and 34% 3-year survival. Outcomes were comparable in patients who progressed through first-line therapy and patients who achieved CR/PR and subsequently relapsed within 6 months. A majority exhibited high-risk features and had intermediate to high risk IPI, which correlated with inferior outcomes. There was no difference in outcomes between patients who received single-agent salvage regimens and patients who underwent traditional, multi-agent salvage regimens. Thus, participation in well-designed clinical trials should be encouraged in this population. Additionally, there may be a trend toward improved EFS and OS in patients who underwent autologous or allogeneic SCT compared to patients who achieved CR or PR but were not transplanted.

SUBMITTER: Zhang JY 

PROVIDER: S-EPMC5803354 | biostudies-literature | 2018 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

Survival following salvage therapy for primary refractory peripheral T-cell lymphomas (PTCL).

Zhang Janie Y JY   Briski Robert R   Devata Sumana S   Kaminski Mark S MS   Phillips Tycel J TJ   Mayer Tera L TL   Bailey Nathanael G NG   Wilcox Ryan A RA  

American journal of hematology 20171218 3


Optimal salvage therapy for primary refractory peripheral T-cell lymphomas (PTCL) and the role of hematopoietic stem cell transplant (SCT) remain poorly defined. We conducted a retrospective review of clinical outcomes and prognostic factors in a single-center cohort of 93 patients with primary refractory PTCL, defined as progression during first-line therapy or relapse within 6 months of its completion. Clinical outcomes were poor in this population, with median event-free survival (EFS) of 3.5  ...[more]

Similar Datasets

| S-EPMC7329607 | biostudies-literature
| PRJNA663004 | ENA
| S-EPMC8288676 | biostudies-literature
| S-EPMC8162056 | biostudies-literature
| S-EPMC7738829 | biostudies-literature
| S-EPMC8064157 | biostudies-literature
| S-EPMC7866778 | biostudies-literature
| S-EPMC8117509 | biostudies-literature
| S-EPMC3410971 | biostudies-literature
| S-EPMC10398948 | biostudies-literature